Cogent Biosciences (COGT) vs Dianthus Therapeutics (DNTH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Dianthus Therapeutics (DNTH) has outperformed Cogent Biosciences (COGT) over the past year, gaining 144.6% versus a gain of 95.2%. Over five years, COGT leads with a +226.2% price change compared with -21.2% for DNTH. Cogent Biosciences is the larger company by market cap ($5.23 billion vs $4.75 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COGT | DNTH |
|---|---|---|
| Share price | $30.14 | $84.88 |
| Market cap | $5.23B | $4.75B |
| 1-day change | -0.79% | -0.61% |
| YTD return | -15.15% | +105.97% |
| 1-year return | +95.21% | +144.61% |
| 5-year return | +226.19% | -21.17% |
| EPS (TTM) | $-2.16 | $-4.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.04M |
| Revenue growth (YoY) | — | -67.35% |
| Net income (latest FY) | $-328.94M | $-162.34M |
| Operating margin | — | -8739.34% |
| Net margin | — | -7973.33% |
| 52-week high | $43.73 | $117.88 |
| 52-week low | $13.78 | $32.22 |
| Distance from 52-week high | -31.08% | -27.99% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +85.20% | +65.88% |
| Average volume | 1.94M | 825.33K |
| Shares outstanding | 173.52M | 55.93M |
| Employees | 258 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNTH has outperformed COGT by 49.4 percentage points over the past year.
About Cogent Biosciences
COGT stock →Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
About Dianthus Therapeutics
DNTH stock →Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
COGT vs DNTH FAQ
Which is bigger, Cogent Biosciences or Dianthus Therapeutics?
Cogent Biosciences (COGT) is larger, with a market capitalization of $5.23B compared with $4.75B for Dianthus Therapeutics (DNTH).
Which stock has performed better over the past year, COGT or DNTH?
DNTH returned +144.61% over the past 12 months, compared with +95.21% for COGT (price return, excluding dividends). Past performance does not predict future results.
Are Cogent Biosciences and Dianthus Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.